Thursday, September 16, 2004

Surprise, Surprise
Unintended Consequences of FDA Antidepressant Meeting

On CBS MarketWatch, we learn that the stocks of antidepressant drug makers went up after the FDA met to formulate recommendations for the use of their products in children and adolescents.  In this post, I comment on the meaning of the statements made by the FDA, try to explain why some panel members contradicted others, and get into the issue of risk-benefit decisions.  Although the recent FDA meeting only addressed the risk-benefit question in children and adolescents, the same concepts apply to adults.  Read the rest at The Rest of the Story.